Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism. Aberrant production of TSLP has been observed in several type 2 allergic disorders such as bronchial asthma, atopic dermatitis and allergic rhinitis, prompting the development of anti-TSLP agents. In this review, we present the current known pharmacodynamics, pharmacokinetics, efficacy, safety and ongoing trials of tezepelumab. Tezepelumab (AMG-157, MEDI-9929) is a fully human immunoglobulin G subclass 2 (lgG2)anti-TSLP monoclonal antibody under investigation for the treatment of moderate to severe asthma. A phase 11 study has concluded that subcutaneously administered tezepelumab at doses of 210 mg every 4 weeks reduces exacerbation rates of asthma other than the type 2 endotype, improves lung function in asthmatic patients, and reduces levels of biomarkers of type 2 inflammation. Tezepelumab was generally well-tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events.